Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding Veklury, Core Product Sales Grow
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.
